ABSI ABSCI CORP

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025.

Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at  or follow us on LinkedIn (), X () and .

Investor Contact

Alex Khan

VP, Finance & Investor Relations

Media Contact



EN
30/07/2025

Underlying

ABSIABSCI CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ABSCI CORP

 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci to Report Business Updates and Second Quarter 2025 Financial and...

Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025 VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacifi...

July 30, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
SNV Synovus Financi...
SIGI Selective Insur... ... (+12)

InsiderInsights.com Daily Ratings Report: July 29, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

SNV SYNOVUS FINANCIAL CORP.
SIGI SELECTIVE INSURANCE GROUP INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
MOFG MIDWESTONE FINANCIAL GROUP
CNC CENTENE CORPORATION
BUSE FIRST BUSEY CORPORATION
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
SONO SONOS
PCB PACIFIC CITY FINANCIAL CORP
ABSI ABSCI CORP
NEGG NEWEGG COMMERCE INC.
07/30/25 July 30, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Announces Pricing of Public Offering of Common Stock

Absci Announces Pricing of Public Offering of Common Stock VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares o...

July 25, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Announces Proposed Public Offering of Common Stock

Absci Announces Proposed Public Offering of Common Stock VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten public offering of $50 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci. Ab...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

Absci Appoints Biopharma Leader Mary Szela to Board of Directors Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal role...

July 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch